{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:19:44Z","timestamp":1792041584684,"version":"4.4.0"},"reference-count":126,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":721,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite progress in elucidation of disease mechanisms, identification of risk factors, biomarker discovery, and the approval of two medications to slow lung function decline in idiopathic pulmonary fibrosis and one medication to slow lung function decline in progressive pulmonary fibrosis, pulmonary fibrosis remains a disease with a high morbidity and mortality. In recognition of the need to catalyze ongoing advances and collaboration in the field of pulmonary fibrosis, the NHLBI, the Three Lakes Foundation, and the Pulmonary Fibrosis Foundation hosted the Pulmonary Fibrosis Stakeholder Summit on November 8\u20139, 2022. This workshop was held virtually and was organized into three topic areas: 1) novel models and research tools to better study pulmonary fibrosis and uncover new therapies, 2) early disease risk factors and methods to improve diagnosis, and 3) innovative approaches toward clinical trial design for pulmonary fibrosis. In this workshop report, we summarize the content of the presentations and discussions, enumerating research opportunities for advancing our understanding of the pathogenesis, treatment, and outcomes of pulmonary fibrosis.<\/jats:p>","DOI":"10.1164\/rccm.202307-1154ws","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T15:49:16Z","timestamp":1703000956000},"page":"362-373","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":21,"title":["Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report"],"prefix":"10.1093","volume":"209","author":[{"given":"Sydney B.","family":"Montesi","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5323-9507","authenticated-orcid":false,"given":"Christian R.","family":"Gomez","sequence":"additional","affiliation":[{"name":"Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-3209","authenticated-orcid":false,"given":"Michael","family":"Beers","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Brown","sequence":"additional","affiliation":[{"name":"Program in Neurotherapeutics, University of Massachusetts Chan Medical School, Worchester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishanu","family":"Chattopadhyay","sequence":"additional","affiliation":[{"name":"Deparment of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7686-0291","authenticated-orcid":false,"given":"Kevin R.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0771-1249","authenticated-orcid":false,"given":"Christine Kim","family":"Garcia","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1809-723X","authenticated-orcid":false,"given":"Brigitte","family":"Gomperts","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, David Geffen School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida P.","family":"Hariri","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine and"},{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory M.","family":"Hogaboam","sequence":"additional","affiliation":[{"name":"Women\u2019s Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-2119","authenticated-orcid":false,"given":"R. Gisli","family":"Jenkins","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5917-4601","authenticated-orcid":false,"given":"Naftali","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1225-3489","authenticated-orcid":false,"given":"Grace Hyun J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Center for Computer Vision and Imaging Biomarkers, Department of Radiological Sciences, David Geffen School of Medicine, and"},{"name":"Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-5128","authenticated-orcid":false,"given":"Melanie","family":"K\u00f6nigshoff","sequence":"additional","affiliation":[{"name":"Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-1467","authenticated-orcid":false,"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[{"name":"Division of Respirology, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell N.","family":"Kotton","sequence":"additional","affiliation":[{"name":"Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8923-1344","authenticated-orcid":false,"given":"Jonathan A.","family":"Kropski","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lasky","sequence":"additional","affiliation":[{"name":"Pulmonary Fibrosis Foundation, Chicago, Illinois"},{"name":"Department of Medicine, Tulane University, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6988-8584","authenticated-orcid":false,"given":"Chelsea M.","family":"Magin","sequence":"additional","affiliation":[{"name":"Department of Bioengineering"},{"name":"Department of Pediatrics"},{"name":"Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McCormick","sequence":"additional","affiliation":[{"name":"Pulmonary Fibrosis Foundation, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-745X","authenticated-orcid":false,"given":"Bethany B.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Nickerson-Nutter","sequence":"additional","affiliation":[{"name":"Three Lakes Foundation, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4957-8869","authenticated-orcid":false,"given":"Justin","family":"Oldham","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9559-1485","authenticated-orcid":false,"given":"Anna J.","family":"Podolanczuk","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Raghu","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Sleep and Critical Care Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Rosas","sequence":"additional","affiliation":[{"name":"Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Pulmonary Fibrosis Foundation, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6743-8443","authenticated-orcid":false,"given":"David","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Shore","sequence":"additional","affiliation":[{"name":"Pulmonary Fibrosis Foundation, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathie","family":"Spino","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Matthew","family":"Craig","sequence":"additional","affiliation":[{"name":"Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-3182","authenticated-orcid":false,"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2026012204225026100_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1164\/rccm.201306-1141WS","article-title":"Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report","volume":"189","author":"Blackwell","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib2","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012204225026100_bib3","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012204225026100_bib4","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012204225026100_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1165\/rcmb.2017-0096ST","article-title":"An official American Thoracic Society workshop report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis","volume":"56","author":"Jenkins","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012204225026100_bib6","doi-asserted-by":"crossref","first-page":"1702133","DOI":"10.1183\/13993003.02133-2017","article-title":"Optimising experimental research in respiratory diseases: an ERS statement","volume":"51","author":"Bonniaud","year":"2018","journal-title":"Eur Respir J"},{"key":"2026012204225026100_bib7","first-page":"A5989","article-title":"Mucus matters: bleomycin induced pulmonary fibrosis in ferrets is sustained and recapitulates features of human idiopathic pulmonary fibrosis [abstract]","author":"Lever","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-022-04552-0","article-title":"Human distal airways contain a multipotent secretory cell that can regenerate alveoli","volume":"604","author":"Basil","year":"2022","journal-title":"Nature"},{"issue":"Suppl 2","key":"2026012204225026100_bib9","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1513\/AnnalsATS.201503-110AW","article-title":"MUC5B and idiopathic pulmonary fibrosis","volume":"12","author":"Yang","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026012204225026100_bib10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/thx.2004.026336","article-title":"Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF","volume":"59","author":"Lawson","year":"2004","journal-title":"Thorax"},{"key":"2026012204225026100_bib11","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1172\/JCI99287","article-title":"Expression of mutant Sftpc in murine alveolar epithelia drives spontaneous lung fibrosis","volume":"128","author":"Nureki","year":"2018","journal-title":"J Clin Invest"},{"key":"2026012204225026100_bib12","first-page":"e126125","article-title":"An SFTPC BRICHOS mutant links epithelial ER stress and spontaneous lung fibrosis","volume":"4","author":"Katzen","year":"2019","journal-title":"JCI Insight"},{"key":"2026012204225026100_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1165\/rcmb.2013-0094TR","article-title":"Animal models of fibrotic lung disease","volume":"49","author":"Moore","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012204225026100_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1165\/rcmb.2019-0276TR","article-title":"Applications and approaches for 3D precision-cut lung slices: disease modeling and drug discovery","volume":"62","author":"Alsafadi","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012204225026100_bib15","first-page":"e58437","article-title":"Generation of human 3D lung tissue cultures (3D-LTCs) for disease modeling","volume":"(144)","author":"Gerckens","year":"2019","journal-title":"J Vis Exp"},{"key":"2026012204225026100_bib16","doi-asserted-by":"crossref","first-page":"L896","DOI":"10.1152\/ajplung.00084.2017","article-title":"An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices","volume":"312","author":"Alsafadi","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012204225026100_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12931-018-0876-y","article-title":"Differential effects of nintedanib and pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis","volume":"19","author":"Lehmann","year":"2018","journal-title":"Respir Res"},{"key":"2026012204225026100_bib18","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.202010-3832OC","article-title":"Saracatinib, a selective Src kinase inhibitor, blocks fibrotic responses in preclinical models of pulmonary fibrosis","volume":"206","author":"Ahangari","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/rccm.202008-3100OC","article-title":"CD148 deficiency in fibroblasts promotes the development of pulmonary fibrosis","volume":"204","author":"Tsoyi","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib20","doi-asserted-by":"crossref","first-page":"eabb3673","DOI":"10.1126\/sciadv.abb3673","article-title":"Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics","volume":"7","author":"Gerckens","year":"2021","journal-title":"Sci Adv"},{"key":"2026012204225026100_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12195-022-00726-y","article-title":"Engineering hybrid-hydrogels comprised of healthy or diseased decellularized extracellular matrix to study pulmonary fibrosis","volume":"15","author":"Saleh","year":"2022","journal-title":"Cell Mol Bioeng"},{"key":"2026012204225026100_bib22","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1039\/D0TB00613K","article-title":"Clickable decellularized extracellular matrix as a new tool for building hybrid-hydrogels to model chronic fibrotic diseases in vitro","volume":"8","author":"Petrou","year":"2020","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"2026012204225026100_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1165\/rcmb.2019-0232MA","article-title":"Embedding of precision-cut lung slices in engineered hydrogel biomaterials supports extended ex vivo culture","volume":"62","author":"Bailey","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012204225026100_bib24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.5966\/sctm.2016-0192","article-title":"Development of a three-dimensional bioengineering technology to generate lung tissue for personalized disease modeling","volume":"6","author":"Wilkinson","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"2026012204225026100_bib25","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1002\/cpsc.56","article-title":"Development of a three-dimensional bioengineering technology to generate lung tissue for personalized disease modeling","volume":"46","author":"Wilkinson","year":"2018","journal-title":"Curr Protoc Stem Cell Biol"},{"key":"2026012204225026100_bib26","doi-asserted-by":"crossref","first-page":"L889","DOI":"10.1152\/ajplung.00446.2015","article-title":"A three-dimensional human model of the fibroblast activation that accompanies bronchopulmonary dysplasia identifies Notch-mediated pathophysiology","volume":"310","author":"Sucre","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012204225026100_bib27","doi-asserted-by":"crossref","first-page":"L186","DOI":"10.1152\/ajplung.00477.2016","article-title":"Posttranslational modification of \u03b2-catenin is associated with pathogenic fibroblastic changes in bronchopulmonary dysplasia","volume":"312","author":"Sucre","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012204225026100_bib28","first-page":"4327","article-title":"Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector","author":"Sommer","year":"2012","journal-title":"J Vis Exp"},{"key":"2026012204225026100_bib29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.stem.2017.08.014","article-title":"Differentiation of human pluripotent stem cells into functional lung alveolar epithelial cells","volume":"21","author":"Jacob","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2026012204225026100_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.stem.2020.09.017","article-title":"Derivation of airway basal stem cells from human pluripotent stem cells","volume":"28","author":"Hawkins","year":"2021","journal-title":"Cell Stem Cell"},{"key":"2026012204225026100_bib31","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-physiol-041520-092904","article-title":"Epithelial stem and progenitor cells in lung repair and regeneration","volume":"83","author":"Alysandratos","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"2026012204225026100_bib32","doi-asserted-by":"crossref","first-page":"109636","DOI":"10.1016\/j.celrep.2021.109636","article-title":"Patient-specific iPSCs carrying an SFTPC mutation reveal the intrinsic alveolar epithelial dysfunction at the inception of interstitial lung disease","volume":"36","author":"Alysandratos","year":"2021","journal-title":"Cell Rep"},{"key":"2026012204225026100_bib33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.stem.2020.02.011","article-title":"Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery","volume":"26","author":"Sharma","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2026012204225026100_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-physiol-032922-082826","article-title":"Lung cell atlases in health and disease","volume":"85","author":"Adams","year":"2023","journal-title":"Annu Rev Physiol"},{"key":"2026012204225026100_bib35","doi-asserted-by":"crossref","first-page":"1802441","DOI":"10.1183\/13993003.02441-2018","article-title":"Proliferating SPP1\/MERTK-expressing macrophages in idiopathic pulmonary fibrosis","volume":"54","author":"Morse","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012204225026100_bib36","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1164\/rccm.201712-2410OC","article-title":"Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis","volume":"199","author":"Reyfman","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib37","doi-asserted-by":"crossref","first-page":"eaba1983","DOI":"10.1126\/sciadv.aba1983","article-title":"Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis","volume":"6","author":"Adams","year":"2020","journal-title":"Sci Adv"},{"key":"2026012204225026100_bib38","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1016\/j.cell.2021.11.033","article-title":"SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis","volume":"184","author":"Wendisch","year":"2021","journal-title":"Cell"},{"key":"2026012204225026100_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40246-022-00393-0","article-title":"From COVID to fibrosis: lessons from single-cell analyses of the human lung","volume":"16","author":"Justet","year":"2022","journal-title":"Hum Genomics"},{"key":"2026012204225026100_bib40","doi-asserted-by":"crossref","first-page":"eaba1972","DOI":"10.1126\/sciadv.aba1972","article-title":"Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis","volume":"6","author":"Habermann","year":"2020","journal-title":"Sci Adv"},{"key":"2026012204225026100_bib41","doi-asserted-by":"crossref","first-page":"595811","DOI":"10.3389\/fimmu.2021.595811","article-title":"Disparate interferon signaling and shared aberrant basaloid cells in single-cell profiling of idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Valenzi","year":"2021","journal-title":"Front Immunol"},{"key":"2026012204225026100_bib42","doi-asserted-by":"crossref","first-page":"L887","DOI":"10.1152\/ajplung.00451.2020","article-title":"The idiopathic pulmonary fibrosis cell atlas","volume":"319","author":"Neumark","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012204225026100_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide\u2014identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl Med Commun"},{"key":"2026012204225026100_bib44","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/17460441.2020.1755252","article-title":"Current models of pulmonary fibrosis for future drug discovery efforts","volume":"15","author":"Yanagihara","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"2026012204225026100_bib45","doi-asserted-by":"crossref","first-page":"1901105","DOI":"10.1183\/13993003.01105-2019","article-title":"The importance of interventional timing in the bleomycin model of pulmonary fibrosis","volume":"55","author":"Kolb","year":"2020","journal-title":"Eur Respir J"},{"key":"2026012204225026100_bib46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.biocel.2007.08.011","article-title":"The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?","volume":"40","author":"Moeller","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"2026012204225026100_bib47","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1164\/rccm.201703-0555OC","article-title":"High-attenuation areas on chest computed tomography and clinical respiratory outcomes in community-dwelling adults","volume":"196","author":"Podolanczuk","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib48","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1183\/13993003.00129-2016","article-title":"High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study","volume":"48","author":"Podolanczuk","year":"2016","journal-title":"Eur Respir J"},{"key":"2026012204225026100_bib49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.2016.0518","article-title":"Association between interstitial lung abnormalities and all-cause mortality","volume":"315","author":"Putman","year":"2016","journal-title":"JAMA"},{"key":"2026012204225026100_bib50","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1056\/NEJMoa1216076","article-title":"MUC5B promoter polymorphism and interstitial lung abnormalities","volume":"368","author":"Hunninghake","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012204225026100_bib51","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJMoa1007285","article-title":"Lung volumes and emphysema in smokers with interstitial lung abnormalities","volume":"364","author":"Washko","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012204225026100_bib52","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.202110-2412OC","article-title":"Reticulation is a risk factor of progressive subpleural nonfibrotic interstitial lung abnormalities","volume":"206","author":"Zhang","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1164\/rccm.202203-0550OC","article-title":"Suspected interstitial lung disease in COPDGene Study","volume":"207","author":"Rose","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib54","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","article-title":"Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society","volume":"8","author":"Hatabu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012204225026100_bib55","doi-asserted-by":"crossref","first-page":"2101814","DOI":"10.1183\/13993003.01814-2021","article-title":"Interstitial lung abnormalities are associated with decreased mean telomere length","volume":"60","author":"Putman","year":"2022","journal-title":"Eur Respir J"},{"key":"2026012204225026100_bib56","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1164\/rccm.201903-0511OC","article-title":"Overlap of genetic risk between interstitial lung abnormalities and idiopathic pulmonary fibrosis","volume":"200","author":"Hobbs","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib57","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1164\/rccm.201909-1834OC","article-title":"Development and progression of radiologic abnormalities in individuals at risk for familial ILD","volume":"201","author":"Salisbury","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib58","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1164\/rccm.202206-1075OC","article-title":"Incidence and progression of fibrotic lung disease in an at-risk cohort","volume":"207","author":"Steele","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib59","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1164\/rccm.202303-0410OC","article-title":"Long-term follow-up of interstitial lung abnormality: implication in follow-up strategy and risk thresholds","volume":"208","author":"Park","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib60","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1513\/AnnalsATS.202303-188PS","article-title":"Approach to clinical trials for the prevention of pulmonary fibrosis","volume":"20","author":"Kim","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2026012204225026100_bib61","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","article-title":"A common MUC5B promoter polymorphism and pulmonary fibrosis","volume":"364","author":"Seibold","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012204225026100_bib62","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat Genet"},{"key":"2026012204225026100_bib63","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/thoraxjnl-2021-218577","article-title":"Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis","volume":"77","author":"Allen","year":"2022","journal-title":"Thorax"},{"key":"2026012204225026100_bib64","doi-asserted-by":"crossref","first-page":"2103132","DOI":"10.1183\/13993003.03132-2021","article-title":"Genetic overlap between idiopathic pulmonary fibrosis and COVID-19","volume":"60","author":"Allen","year":"2022","journal-title":"Eur Respir J"},{"key":"2026012204225026100_bib65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.202110-2439OC","article-title":"Rare and common variants in KIF15 contribute to genetic risk of idiopathic pulmonary fibrosis","volume":"206","author":"Zhang","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib66","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2213-2600(18)30135-8","article-title":"Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study","volume":"6","author":"Dressen","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026012204225026100_bib67","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1164\/rccm.201610-2088OC","article-title":"An exome sequencing study to assess the role of rare genetic variation in pulmonary fibrosis","volume":"196","author":"Petrovski","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib68","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/humu.24476","article-title":"Rare surfactant-related variants in familial and sporadic pulmonary fibrosis","volume":"43","author":"Sutton","year":"2022","journal-title":"Hum Mutat"},{"key":"2026012204225026100_bib69","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.201810-1891OC","article-title":"Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis","volume":"200","author":"Moore","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib70","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1164\/rccm.202201-0124OC","article-title":"Validation of proposed criteria for progressive pulmonary fibrosis","volume":"207","author":"Pugashetti","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib72","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1164\/rccm.202206-1143LE","article-title":"Progressive pulmonary fibrosis: should the timelines be taken out of the definition?","volume":"206","author":"Cottin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib73","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.202206-1166LE","article-title":"Progressive pulmonary fibrosis: putting the cart before the horse","volume":"206","author":"Johannson","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib74","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1164\/rccm.202205-0910LE","article-title":"Patient characteristics and survival for progressive pulmonary fibrosis using different definitions","volume":"207","author":"Khor","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib75","doi-asserted-by":"crossref","first-page":"2101396","DOI":"10.1183\/13993003.01396-2021","article-title":"Lung function trajectory in progressive fibrosing interstitial lung disease","volume":"59","author":"Oldham","year":"2022","journal-title":"Eur Respir J"},{"key":"2026012204225026100_bib76","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1164\/rccm.201508-1546OC","article-title":"Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis","volume":"194","author":"Ley","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib77","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","article-title":"Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis","volume":"10","author":"Bowman","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026012204225026100_bib78","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1164\/rccm.201711-2174OC","article-title":"Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis","volume":"198","author":"Jacob","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib79","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s00330-019-06402-6","article-title":"Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18-24-month follow-ups","volume":"30","author":"Kim","year":"2020","journal-title":"Eur Radiol"},{"key":"2026012204225026100_bib80","doi-asserted-by":"crossref","first-page":"17534666211004238","DOI":"10.1177\/17534666211004238","article-title":"The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis","volume":"15","author":"Kim","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"2026012204225026100_bib81","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026012204225026100_bib82","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1164\/rccm.201803-0444PP","article-title":"Computed tomographic biomarkers in idiopathic pulmonary fibrosis. The future of quantitative analysis","volume":"199","author":"Wu","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib83","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1164\/rccm.201707-1446LE","article-title":"Endobronchial optical coherence tomography for low-risk microscopic assessment and diagnosis of idiopathic pulmonary fibrosis in vivo","volume":"197","author":"Hariri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib84","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm1450","article-title":"Comprehensive volumetric optical microscopy in vivo","volume":"12","author":"Yun","year":"2006","journal-title":"Nat Med"},{"key":"2026012204225026100_bib85","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1164\/rccm.202104-0847OC","article-title":"Diagnostic accuracy of endobronchial optical coherence tomography for the microscopic diagnosis of usual interstitial pneumonia","volume":"204","author":"Nandy","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib86","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1164\/rccm.202112-2832LE","article-title":"Polarization-sensitive endobronchial optical coherence tomography for microscopic imaging of fibrosis in interstitial lung disease","volume":"206","author":"Nandy","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib87","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.rmed.2006.10.002","article-title":"Patient experiences with pulmonary fibrosis","volume":"101","author":"Collard","year":"2007","journal-title":"Respir Med"},{"key":"2026012204225026100_bib88","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/s41591-022-02010-y","article-title":"Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records","volume":"28","author":"Onishchenko","year":"2022","journal-title":"Nat Med"},{"key":"2026012204225026100_bib89","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026012204225026100_bib90","doi-asserted-by":"crossref","first-page":"2002559","DOI":"10.1183\/13993003.02559-2020","article-title":"Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Hirani","year":"2021","journal-title":"Eur Respir J"},{"key":"2026012204225026100_bib91","doi-asserted-by":"crossref","first-page":"1801992","DOI":"10.1183\/13993003.01992-2018","article-title":"A randomised, placebo-controlled study of omipalisib (PI3K\/mTOR) in idiopathic pulmonary fibrosis","volume":"53","author":"Lukey","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012204225026100_bib92","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12931-020-01339-7","article-title":"A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled \u03b1v\u03b26 integrin inhibitor","volume":"21","author":"Maher","year":"2020","journal-title":"Respir Res"},{"key":"2026012204225026100_bib93","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012204225026100_bib94","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/chem.201801578","article-title":"Molecular probes for imaging fibrosis and fibrogenesis","volume":"25","author":"D\u00e9sog\u00e8re","year":"2019","journal-title":"Chemistry"},{"key":"2026012204225026100_bib95","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1164\/rccm.201903-0503LE","article-title":"Type I collagen-targeted positron emission tomography imaging in idiopathic pulmonary fibrosis: first-in-human studies","volume":"200","author":"Montesi","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib96","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/s41467-019-11863-w","article-title":"Evaluation of integrin \u03b1v\u03b26 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis","volume":"10","author":"Kimura","year":"2019","journal-title":"Nat Commun"},{"key":"2026012204225026100_bib97","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00259-019-04586-z","article-title":"Clinical quantification of the integrin \u03b1v\u03b26 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)","volume":"47","author":"Lukey","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026012204225026100_bib98","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1164\/rccm.202110-2414OC","article-title":"Comprehensive analysis of fibroblast activation protein expression in interstitial lung diseases","volume":"207","author":"Yang","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib99","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","article-title":"68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study","volume":"3","author":"Bergmann","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026012204225026100_bib100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1172\/JCI122132","article-title":"Molecular imaging of fibrosis: recent advances and future directions","volume":"129","author":"Montesi","year":"2019","journal-title":"J Clin Invest"},{"key":"2026012204225026100_bib101","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1001\/jama.2021.4956","article-title":"Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: the CleanUP-IPF randomized clinical trial","volume":"325","author":"Martinez","year":"2021","journal-title":"JAMA"},{"key":"2026012204225026100_bib102","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1001\/jama.2020.22960","article-title":"Effect of co-trimoxazole (trimethoprim-sulfamethoxazole) vs placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis: the EME-TIPAC randomized clinical trial","volume":"324","author":"Wilson","year":"2020","journal-title":"JAMA"},{"key":"2026012204225026100_bib103","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s12890-022-02281-8","article-title":"Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial","volume":"22","author":"Podolanczuk","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026012204225026100_bib104","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012204225026100_bib105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ana.26285","article-title":"Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development","volume":"91","author":"Paganoni","year":"2022","journal-title":"Ann Neurol"},{"key":"2026012204225026100_bib106","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","author":"Angus","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026012204225026100_bib107","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"key":"2026012204225026100_bib108","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa030511","article-title":"A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis","volume":"350","author":"Raghu","year":"2004","journal-title":"N Engl J Med"},{"key":"2026012204225026100_bib109","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","article-title":"BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"184","author":"King","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib110","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201201-0006PP","article-title":"Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials","volume":"185","author":"Raghu","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib111","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1164\/rccm.201311-1951OC","article-title":"All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials","volume":"189","author":"King","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib112","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7","article-title":"Combining mortality and longitudinal measures in clinical trials","volume":"18","author":"Finkelstein","year":"1999","journal-title":"Stat Med"},{"key":"2026012204225026100_bib113","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012204225026100_bib114","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","article-title":"Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis","volume":"194","author":"Russell","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/sim.7064","article-title":"Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials","volume":"36","author":"Lipkovich","year":"2017","journal-title":"Stat Med"},{"key":"2026012204225026100_bib116","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cjs.11701","article-title":"Integrating information from existing risk prediction models with no model details","volume":"51","author":"Han","year":"2023","journal-title":"Can J Stat"},{"key":"2026012204225026100_bib117","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/sim.9252","article-title":"Improving main analysis by borrowing information from auxiliary data","volume":"41","author":"Chen","year":"2022","journal-title":"Stat Med"},{"key":"2026012204225026100_bib118","first-page":"1321","article-title":"Empirical likelihood estimation using auxiliary summary information with different covariate distributions","volume":"29","author":"Han","year":"2019","journal-title":"Stat Sin"},{"key":"2026012204225026100_bib119","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/biomet\/asac022","article-title":"Data integration: exploiting ratios of parameter estimates from a reduced external model","volume":"110","author":"Taylor","year":"2022","journal-title":"Biometrika"},{"key":"2026012204225026100_bib120","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/10618600.2022.2050248","article-title":"Data integration with oracle use of external information from heterogeneous populations","volume":"31","author":"Zhai","year":"2022","journal-title":"J Comput Graph Stat"},{"key":"2026012204225026100_bib121","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/biomet\/asz030","article-title":"Generalized meta-analysis for multiple regression models across studies with disparate covariate information","volume":"106","author":"Kundu","year":"2019","journal-title":"Biometrika"},{"key":"2026012204225026100_bib122","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/01621459.2015.1123157","article-title":"Constrained maximum likelihood estimation for model calibration using summary-level information from external big data sources","volume":"111","author":"Chatterjee","year":"2016","journal-title":"J Am Stat Assoc"},{"key":"2026012204225026100_bib123","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1378\/chest.11-2602","article-title":"Patient-reported outcomes in idiopathic pulmonary fibrosis research","volume":"142","author":"Swigris","year":"2012","journal-title":"Chest"},{"key":"2026012204225026100_bib124","doi-asserted-by":"crossref","first-page":"e000363","DOI":"10.1136\/bmjresp-2018-000363","article-title":"The King\u2019s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference","volume":"6","author":"Sinha","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2026012204225026100_bib125","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1164\/rccm.202002-0415OC","article-title":"Development and initial validation analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire","volume":"202","author":"Swigris","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204225026100_bib126","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.202208-1504OC","article-title":"Validity and reliability of the Fatigue Severity Scale in a real-world interstitial lung disease cohort","volume":"208","author":"Aronson","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/209\/4\/362\/66431365\/ajrccm_209_4_362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/209\/4\/362\/66431365\/ajrccm_209_4_362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:23:31Z","timestamp":1769073811000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/209\/4\/362\/8427579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":126,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2,15]]},"published-print":{"date-parts":[[2024,2,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202307-1154ws","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}